

## Calendar No. 443

117TH CONGRESS  
2D SESSION

# H. R. 1193

---

IN THE SENATE OF THE UNITED STATES

DECEMBER 9, 2021

Received

MAY 25, 2022

Read twice and referred to the Committee on Health, Education, Labor, and  
Pensions

JULY 12, 2022

Reported by Mrs. MURRAY, with an amendment

[Strike out all after the enacting clause and insert the part printed in italic]

---

## AN ACT

To amend title IV of the Public Health Service Act to direct the Director of the National Institutes of Health, in consultation with the Director of the National Heart, Lung, and Blood Institute, to establish a program under which the Director of the National Institutes of Health shall support or conduct research on valvular heart disease, and for other purposes.

1        *Be it enacted by the Senate and House of Representa-*  
 2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4        This Act may be cited as the “Cardiovascular Ad-  
 5 vances in Research and Opportunities Legacy Act”.

6 **SEC. 2. GRANTS FOR VALVULAR HEART DISEASE RE-**  
 7 **SEARCH.**

8        Subpart 2 of part C of title IV of the Public Health  
 9 Service Act (42 U.S.C. 285b et seq.) is amended by insert-  
 10 ing after section 424C (42 U.S.C. 285b–7e) the following:

11 **“SEC. 424D. GRANTS FOR VALVULAR HEART DISEASE RE-**  
 12 **SEARCH.**

13        “(a) **IN GENERAL.**—The Director of the National In-  
 14 stitutes of Health, in consultation with the Director of the  
 15 Institute, shall support or conduct research regarding val-  
 16 vular heart disease.

17        “(b) **SUPPORT GUIDELINES.**—The distribution of  
 18 funding authorized under subsection (a) may be used to  
 19 pursue the following outcomes:

20            “(1) Using precision medicine and advanced  
 21 technological imaging to generate data on individ-  
 22 uals with valvular heart disease.

23            “(2) Identifying and developing a cohort of in-  
 24 dividuals with valvular heart disease and available  
 25 data.

1           “(3) Corroborating data generated through clinical trials to develop a prediction model to distinguish individuals at high risk for sudden cardiac arrest or sudden cardiac death from valvular heart disease.

2           “(4) For other outcomes needed to acquire necessary data on valvular heart disease.

3           “(e) MITRAL VALVE PROLAPSE WORKSHOP.—Not  
4 later than one year after the date of the enactment of this  
5 section, the Director of the Institute shall convene a workshop composed of subject matter experts and stakeholders  
6 to identify research needs and opportunities to develop  
7 prescriptive guidelines for treatment of individuals with  
8 mitral valve prolapse.

9           “(d) AUTHORIZATION OF APPROPRIATIONS.—For the  
10 purpose of carrying out this section, there is authorized  
11 to be appropriated \$20,000,000 for each of fiscal years  
12 2022 through 2026.”.

13 **SEC. 3. PROGRAMS OF CENTERS FOR DISEASE CONTROL**  
14 **AND PREVENTION.**

15           Part B of title III of the Public Health Service Act  
16 (42 U.S.C. 243 et seq.) is amended by inserting after section  
17 312 the following section:  
18

1 **“SEC. 312A. PREVENTION OF SUDDEN CARDIAC DEATH AS A**  
2 **RESULT OF VALVULAR HEART DISEASE.**

3 “(a) IN GENERAL.—The Secretary, acting through  
4 the Director of the Centers for Disease Control and Pre-  
5 vention, may carry out projects to increase education,  
6 awareness, or diagnosis of valvular heart disease and to  
7 reduce the incidence of sudden cardiac death caused by  
8 valvular heart disease. Such projects may be carried out  
9 by the Secretary directly or through awards of grants or  
10 contracts to public or nonprofit private entities. The Sec-  
11 retary may directly (or through such awards) provide tech-  
12 nical assistance with respect to the planning, development,  
13 and operation of such projects.

14 “(b) CERTAIN ACTIVITIES.—Upon availability of ap-  
15 plicable data, projects carried out under subsection (a)  
16 may include—

17 “(1) continuing the activities at the Division for  
18 Heart Disease and Stroke Prevention, including  
19 those related to valvular heart disease;

20 “(2) broadening the awareness of the public  
21 concerning the risk factors for, the symptoms of,  
22 and the public health consequences of valvular heart  
23 disease; and

24 “(3) enhancing surveillance of out-of-hospital  
25 cardiac arrests to improve patient outcomes.

1       “(e) GRANT PRIORITIZATION.—The Secretary may,  
2 in awarding grants or entering into contracts pursuant to  
3 subsection (a), give priority to entities seeking to carry  
4 out projects that target populations most impacted by val-  
5 vular heart disease.

6       “(d) COORDINATION OF ACTIVITIES.—The Secretary  
7 shall ensure that activities under this section are coordi-  
8 nated, as appropriate, with other agencies of the Public  
9 Health Service that carry out activities regarding valvular  
10 heart disease.

11       “(e) BEST PRACTICES.—The Secretary, acting  
12 through the Director of the Centers for Disease Control  
13 and Prevention, shall—

14               “(1) collect and analyze the findings of research  
15               conducted with respect to valvular heart disease; and

16               “(2) taking into account such findings, publish  
17               on the website of the Centers for Disease Control  
18               and Prevention best practices for physicians and  
19               other health care providers who provide care to indi-  
20               viduals with valvular heart disease.”.

21 **SECTION 1. SHORT TITLE.**

22       *This Act may be cited as the “Cardiovascular Ad-*  
23 *vances in Research and Opportunities Legacy Act”.*

1 **SEC. 2. HHS VALVULAR HEART DISEASE ACTIVITIES.**

2 (a) *IN GENERAL.*—*The Secretary of Health and*  
3 *Human Services (referred to in this section as the “Sec-*  
4 *retary”)* shall, as appropriate, continue activities related  
5 *to research, education, and awareness of valvular heart dis-*  
6 *eases.*

7 (b) *NIH RESEARCH RELATED TO VALVULAR HEART*  
8 *DISEASES.*—

9 (1) *IN GENERAL.*—*The Director of the National*  
10 *Institutes of Health, in consultation with the Director*  
11 *of the National Heart, Lung, and Blood Institute,*  
12 *may support or conduct research regarding valvular*  
13 *heart diseases.*

14 (2) *SUPPORT FURTHER RESEARCH.*—*In order to*  
15 *improve information on, and understanding of, cau-*  
16 *sation and risk factors for valvular heart diseases, re-*  
17 *search conducted or supported under this subsection*  
18 *for such diseases may include the following:*

19 (A) *Use of advanced technological imaging*  
20 *and other relevant methods to generate data re-*  
21 *lated to valvular heart diseases.*

22 (B) *Assessing potential risk factors for sud-*  
23 *den cardiac arrest or sudden cardiac death from*  
24 *valvular heart diseases.*

25 (C) *Other activities, as appropriate, in*  
26 *order to improve the availability of information*

1           on, and advance research related to, valvular  
2           heart diseases.

3           (3) *MITRAL VALVE PROLAPSE WORKSHOP.*—Not  
4           later than one year after the date of enactment of this  
5           Act, the Director of the National Heart, Lung, and  
6           Blood Institute shall, as appropriate, convene a work-  
7           shop composed of subject matter experts and stake-  
8           holders to identify research needs and opportunities to  
9           develop recommendations for the identification and  
10          treatment of individuals with mitral valve prolapse,  
11          including such individuals who may be at risk for  
12          sudden cardiac arrest or sudden cardiac death.

13          (c) *PREVENTION ACTIVITIES TO IMPROVE AWARENESS*  
14 *OF SUDDEN CARDIAC DEATH AS A RESULT OF VALVULAR*  
15 *HEART DISEASES.*—

16           (1) *IN GENERAL.*—The Secretary may carry out  
17          activities to increase education and awareness of val-  
18          vular heart diseases in order to reduce the incidence  
19          of sudden cardiac death caused by such diseases. The  
20          Secretary may—

21                   (A) award grants or contracts to public or  
22                   nonprofit private entities to carry out activities  
23                   under this subsection; and

1           (B) may directly, or through grants or con-  
2           tracts, provide technical assistance with respect  
3           to such activities.

4           (2) *CERTAIN ACTIVITIES.*—Upon availability of  
5           applicable data, projects carried out under paragraph  
6           (1) may include—

7           (A) continuing activities at the Centers for  
8           Disease Control and Prevention related to val-  
9           vular heart diseases;

10          (B) improving the awareness of the public  
11          concerning any risk factors for, the symptoms of,  
12          and the public health impact of, valvular heart  
13          diseases; and

14          (C) improving the availability of public  
15          health data and information, as appropriate, re-  
16          garding cardiac arrests related to valvular heart  
17          diseases.

18          (3) *GRANT PRIORITIZATION.*—The Secretary  
19          may, in awarding grants or entering into contracts  
20          pursuant to paragraph (1), give priority to entities  
21          seeking to carry out projects for populations most im-  
22          pacted by valvular heart diseases.

23          (4) *COORDINATION OF ACTIVITIES.*—The Sec-  
24          retary shall, as appropriate, ensure that activities  
25          under this section are coordinated with other agencies



1        *and offices of the Department of Health and Human*  
2        *Services that carry out activities regarding valvular*  
3        *heart diseases.*

4            (5) *BEST PRACTICES.—The Secretary shall, as*  
5        *applicable and appropriate, identify and disseminate*  
6        *best practices for relevant health care providers re-*  
7        *lated to valvular heart diseases.*

8            (d) *AUTHORIZATION OF APPROPRIATIONS.—For pur-*  
9        *poses of carrying out this section, there are authorized to*  
10       *be appropriated such sums as may be necessary for each*  
11       *of fiscal years 2023 through 2027.*

Calendar No. 443

117<sup>TH</sup> CONGRESS  
2<sup>D</sup> SESSION

**H. R. 1193**

---

---

**AN ACT**

To amend title IV of the Public Health Service Act to direct the Director of the National Institutes of Health, in consultation with the Director of the National Heart, Lung, and Blood Institute, to establish a program under which the Director of the National Institutes of Health shall support or conduct research on valvular heart disease, and for other purposes.

---

---

JULY 12, 2022

Reported with an amendment